Status | Study |
Terminated |
Study Name: HL2351 CAPS Phase II Study Condition: Cryopyrin‑Associated Periodic Syndromes (CAPS) Date: 2016-05-10 Interventions: Drug: HL2351 The dose will be adjusted based on disease activities |
Active, not recruiting |
Study Name: Continued Access to PREVAIL (CAP2) Condition: Atrial Fibrillation Date: 2012-11-06 Interventions: Device: WATCHMAN LAA Closure Technology |
Completed |
Study Name: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Condition: Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Date: 2012-02-17 Interventions: Drug: ACZ885 |
Completed |
Study Name: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients Condition: Cryopyrin-associated Periodic Syndromes (CAPS) Familial Cold Autoinflam Syn (FCAS) Date: 2010-09-30 |
Withdrawn |
Study Name: A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease Condition: Muckle Wells Syndrome Autoinflammatory Date: 2010-09-29 Interventions: Drug: XOMA 052 |
Completed |
Study Name: The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada Condition: Cryopyrin Associated Periodic Syndrome Date: 2010-03-25 Interventions: Drug: canakinumab (company code: ACZ885D) |
Completed |
Study Name: Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) Condition: Muckle-Wells Syndrome Schnitzler Syndrome Date: 2010-01-07 Interventions: Drug: rilonacept 160mg of rilonacept 1x/week Other N |
Completed |
Study Name: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase Condition: Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Date: 2009-10-06 Interventions: Drug: canakinumab canakinumab |
Completed |
Study Name: Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Condition: Cryopyrin-Associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Date: 2008-05-27 Interventions: Drug: Canakinumab (ACZ885) 6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with |
Completed |
Study Name: Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms Condition: NALP3 Mutation Date: 2007-06-18 Interventions: Drug: canakinumab |